Supplementary Figure S3 from Accelerating Drug Development in Hormone-Naïve Prostate Cancer Through Multimodal Therapy Strategies: the MetaCURE Phase 2 Randomized Clinical Trial

Supplementary Figure S3. Mutational Profile by Cohort and Treatment Group. Distribution of key genomic alterations among patients with metastatic prostate cancer. (Left) Comparison of alteration frequencies between Cohort A and Cohort B. (Right) Comparison of alteration frequencies between treatment groups receiving Apa alone versus Apa + AAP. The most frequently altered genes included TP53, PTEN, SPOP, FOXA1, and AGO2.